Clinical trials: Streptococcus Infection
Pneumonia, Pneumococcal Infections
Safety, Tolerability, Efficacy and Pharmacodynamics of CAL02 in Severe Pneumonia Caused by Streptococcus Pneumoniae
The objectives of this study are to assess the safety, tolerability, clinical and microbiological efficacy and pharmacodynamics of patients who have severe pneumonia caused by Streptococcus pneumoniae after the intravenous…
- Trial name
- NCT02583373
- Testing
- CAL02 Low-dose, CAL02 High-dose
- Where
- 10 sites in Belgium, France
- Volunteers
- 19 people
- Sponsor
- Combioxin SA
Strep Throat
Evaluation of the IND One Step Strep A Rapid Test vs. Culture
The purpose of this study is to demonstrate the ability of the IND One Step Strep A test to accurately test a throat swab specimen from a symptomatic patient for the presence or absence of Group A Streptococcus (Strep A) when…
- Trial name
- NCT01491776
- Where
- 3 sites in United States
- Volunteers
- 315 people
- Sponsor
- IND Diagnostic Inc.
Infections, Streptococcal, Streptococcus Pneumoniae
Impact on Carriage, Acute Otitis Media, Immuno & Safety of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A
The aim of this study is to assess the effectiveness of GSK Biologicals' pneumococcal conjugate vaccine (GSK1024850A) in preventing invasive disease caused by S. pneumoniae or H.
- Trial name
- NCT00839254
- Testing
- Pneumococcal conjugate vaccine Synflorix (GSK1024850A), GSK Biologicals' Engerix TM vaccine (Hepatitis B vaccine), GSK Biologicals' Havrix TM vaccine (Hepatitis A vaccine)
- Where
- 15 sites in Finland
- Volunteers
- 6,181 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumococcal Infections
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Lots of V114 in Healthy Infants (V114-008)
This study is designed to evaluate the safety, tolerability, and immunogenicity of two different lots of V114 in healthy infants 6 to 12 weeks (>=42 days to <=90 days) of age.
- Trial name
- NCT02987972
- Testing
- V114 Lot 1, V114 Lot 2, Prevnar 13™
- Where
- 49 sites in United States, Canada and 4 more
- Volunteers
- 1,051 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Streptococcus Pneumoniae Infections
Clinical Study on the Combined Administration of 15-Valent Pneumococcal Conjugate Vaccine and Diphtheria, Tetanus, Pertussis Vaccine
This clinical study aims to evaluate the mutual influence of combined administration of 15-Valent Pneumococcal Conjugate Vaccine and Diphtheria, Tetanus, Pertussis Vaccine in the target population
- Trial name
- NCT06817187
- Testing
- 15-Valent Pneumococcal Conjugate Vaccine and Diphtheria, Tetanus and Acellular pertussis (Component) Combined Vaccine (Adsorbed), Diphtheria, Tetanus and Acellular pertussis (Component) Combined Vaccine (Adsorbed)
- Where
- China
- Volunteers
- 1,110 people, healthy volunteers welcome
- Sponsor
- Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Pneumococcal Vaccines
A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age
This is a Phase 3, randomized, double-blind study to evaluate the safety and immunogenicity of VAX-31 and seasonal influenza vaccine in pneumococcal-naïve adults ≥ 50 years when the two vaccines are administered at the same visit…
- Trial name
- NCT07365826
- Testing
- 31-valent pneumococcal conjugate vaccine, Seasonal Influenza Vaccine (SIV) (Flublok)
- Where
- 25 sites in United States
- Volunteers
- 1,390 people, healthy volunteers welcome
- Sponsor
- Vaxcyte, Inc.
Pneumococcal Infections
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)
This study is designed 1) to evaluate the safety, tolerability, and immunogenicity of V114 and Prevnar 13™, 2) to describe the safety of sequential administration of V114 or Prevnar 13™ followed by PNEUMOVAX™23, and 3) to…
- Trial name
- PNEU-PATH (NCT03480763)
- Testing
- V114, Prevnar 13™, PNEUMOVAX™23
- Where
- 22 sites in United States, South Korea and 2 more
- Volunteers
- 652 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Pneumococcal Infections
Study Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine
This study will assess the Immunogenicity and safety of 13-valent Pneumococcal Conjugate Vaccine compared with 23-valent Pneumococcal Polysaccharide Vaccine. All participants should be naïve of Pneumococcal vaccine.
- Trial name
- NCT02079207
- Testing
- NBP606, Prodiax-23
- Volunteers
- 767 people, healthy volunteers welcome
- Sponsor
- SK Chemicals Co., Ltd.
Pneumococcal Infections
Study Evaluating Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine With Influenza Vaccine in Adults
The 13-valent pneumococcal conjugate vaccine (13vPnC) is being developed for adults to prevent pneumococcal diseases such as meningitis (inflammation of the brain lining), septicemia (blood poisoning), and pneumonia (inflammation…
- Trial name
- NCT00492557
- Testing
- 13-valent pneumococcal conjugate vaccine, 13vPnC + TIV
- Volunteers
- 1,185 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Infections
Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2/V114-026)
The purpose of this clinical study is to evaluate the safety and immunogenicity of a 3-dose schedule (2-dose primary series followed by a toddler dose) of pneumococcal conjugate vaccine (PCV) as one of the currently recommended…
- Trial name
- PNEU-PED-EU-2 (NCT04016714)
- Testing
- V114, Prevenar 13™, Vaxelis™
- Where
- 24 sites in Denmark, Finland and 3 more
- Volunteers
- 1,191 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Infections, Streptococcal
Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine
This study will evaluate safety, reactogenicity and immunogenicity of GSK Biologicals' pneumococcal conjugate vaccine compared to Prevenar™ when co-administered with DTPw-HBV/Hib and OPV or IPV vaccines, according to 2 different…
- Trial name
- NCT00344318
- Testing
- Pneumococcal conjugate vaccine GSK1024850A, Prevenar, Tritanrix-HepB
- Where
- 7 sites in Philippines, Poland
- Volunteers
- 806 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infections, Streptococcal
Post-marketing Surveillance Study With GSK Biologicals' Pneumococcal Vaccine in Healthy Infants in Philippines
The purpose of this post-marketing surveillance study is to evaluate the safety of Synflorix™ when administered according to the local Prescribing Information to healthy Filipino infants.
- Trial name
- NCT01046097
- Testing
- Synflorix™
- Where
- 2 sites in Philippines
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumococcal Disease
A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults
The purpose of this study is to learn about the safety and immune effects of a pneumococcal vaccine in adults. This vaccine can possibly provide protection against further pneumococcal disease.
- Trial name
- NCT06182124
- Testing
- Multivalent Pneumococcal Vaccine - Formulation 1, Multivalent Pneumococcal Vaccine - Formulation 2, 20-valent pneumococcal conjugate vaccine (20vPnC)
- Where
- 20 sites in United States
- Volunteers
- 1,710 people, healthy volunteers welcome
- Sponsor
- Pfizer
Streptococcal Infections
A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of the GSK 4-component Strep A Vaccine With Aluminum Hydroxide (Alum) or AS37 in Healthy Young Adults
The purpose of this study is to assess the safety of 3 doses of 2 new Strep A vaccine formulations, one with an Alum adjuvant, and the other with AS37 adjuvant.
- Trial name
- NCT07085702
- Testing
- Low dose Strep A Alum, Medium dose Strep A Alum, High dose Strep A Alum
- Where
- 2 sites in Australia
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumococcal Infectious Disease
A Clinical Trial to Observe the Safety of 23-Valent Pneumococcal Polysaccharide Vaccine in Target Population
An open clinical trial of a 23-valent pneumococcal polysaccharide vaccine (PPV23) developed by Sinovac Life Science Co., Ltd was conducted to evaluate the safety of Sinovac PPV23 in target population of individuals aged 2 years…
- Trial name
- NCT07071701
- Testing
- 23-valent pneumococcal polysaccharide vaccine, Influenza vaccine
- Where
- China
- Volunteers
- 19,267 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Infections, Streptococcal
Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6-12wks of Age
The purpose of the present study is to demonstrate that the changes in the manufacturing process for the commercial lot of the pneumococcal conjugate vaccine GSK1024850A have no clinical impact and that the immune responses are…
- Trial name
- NCT00808444
- Testing
- Pneumococcal conjugate vaccine GSK1024850A (different lots), Infanrix hexa, Infanrix-IPV/Hib
- Where
- 5 sites in Malaysia, Singapore
- Volunteers
- 466 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumococcal Disease
Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7)
This study will evaluate the safety, tolerability, and immunogenicity of a pneumococcal 21-valent conjugate vaccine (V116) in persons living with human immunodeficiency virus (HIV), for the prevention of pneumococcal disease…
- Trial name
- NCT05393037
- Testing
- V116, PCV15, PPSV23
- Where
- 20 sites in United States, Belgium and 4 more
- Volunteers
- 313 people
- Sponsor
- Merck Sharp & Dohme LLC
Pneumococcal Meningitis
Study Evaluating Pneumococcal Meningitis in the Paediatric Population in Spain Four Years After the Marketing of Prevenar.
The aim of this study is to determine the prevalence of pneumococcal meningitis in the paediatric population in Spain four years after the marketing of Prevenar.
- Trial name
- NCT00227214
- Where
- 39 sites in Spain
- Volunteers
- 160 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Pneumococcal Infections
A Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine
This an open phase Ⅳ clinical trial of 23-valent pneumococcal polysaccharide vaccine manufactured by Sinovac Biotech Co., Ltd.The purpose of this study is to evaluate the immunity persistence after single dose of 23-valent…
- Trial name
- NCT04989465
- Testing
- Investigational 23-valent PPV, Control 23-valent PPV
- Where
- China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Pneumococcal Infection
Revaccination With PNEUMOVAX™ 23 in Older Japanese Adults (V110-902)
The purpose of this study is to determine if revaccination with pneumococcal vaccine (PNEUMOVAX™ 23, V110) is well tolerated and produces an immune response in older Japanese adults.
- Trial name
- NCT02260882
- Testing
- PNEUMOVAX™ 23
- Volunteers
- 243 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC